CalcciMedica的短期利息因股票增益而下降, CalciMedica's short interest drops as stock gains, with a "buy" rating and positive institutional investor interest.

CalciMedica是一家生物制药公司,1月的利息短幅下降6.6%,少了61 300股。 CalciMedica, a biopharmaceutical company, saw short interest drop by 6.6% in January, with 61,300 shares shorted. 该公司的股票被HC Wainwright定为“购买”,目标价格为16.00美元。 The company's stock is rated "buy" with a $16.00 target price by HC Wainwright. 机构投资者增加了他们的股份，CalciMedica 的主导产品 Auxora 正处于 2 期临床试验中。 Institutional investors have increased their stakes, and CalciMedica's lead product, Auxora, is in phase 2 clinical trials. 股票收盘价为2.64美元, 0.08美元, 市值为3559万美元. The stock closed at $2.64, up $0.08, with a market cap of $35.59 million.